78 related articles for article (PubMed ID: 2910492)
1. Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis-diamminedichloroplatinum(II).
Ruiz L; Gilden J; Jaffe N; Robertson R; Wang YM
Cancer Res; 1989 Feb; 49(3):742-4. PubMed ID: 2910492
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
Canpolat C; Pearson P; Robertson R; Jaffe N
Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
[TBL] [Abstract][Full Text] [Related]
3. cis-Dichlorodiammineplatinum(II) in childhood cancer.
Freeman AI; Ettinger LJ; Brecher ML
Cancer Treat Rep; 1979; 63(9-10):1615-20. PubMed ID: 291483
[TBL] [Abstract][Full Text] [Related]
4. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
5. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
7. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
Knight KR; Kraemer DF; Neuwelt EA
J Clin Oncol; 2005 Dec; 23(34):8588-96. PubMed ID: 16314621
[TBL] [Abstract][Full Text] [Related]
8. A review of cis-platinum ototoxicity.
Moroso MJ; Blair RL
J Otolaryngol; 1983 Dec; 12(6):365-9. PubMed ID: 6686617
[TBL] [Abstract][Full Text] [Related]
9. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
Berrak SG; Pearson M; Berberoğlu S; Ilhan IE; Jaffe N
Pediatr Blood Cancer; 2005 Mar; 44(3):215-9. PubMed ID: 15503294
[TBL] [Abstract][Full Text] [Related]
11. Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors.
Kharasch VS; Lipsitz S; Santis W; Hallowell JA; Goorin A
Med Pediatr Oncol; 1996 Aug; 27(2):85-91. PubMed ID: 8649325
[TBL] [Abstract][Full Text] [Related]
12. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
14. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
15. Recovery from cisplatin-induced ototoxicity: a case report and review.
Truong MT; Winzelberg J; Chang KW
Int J Pediatr Otorhinolaryngol; 2007 Oct; 71(10):1631-8. PubMed ID: 17706797
[TBL] [Abstract][Full Text] [Related]
16. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
17. Ototoxic impact of cisplatin in pediatric oncology patients.
Berg AL; Spitzer JB; Garvin JH
Laryngoscope; 1999 Nov; 109(11):1806-14. PubMed ID: 10569412
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
19. Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion.
Jaffe N; Keifer R; Robertson R; Cangir A; Wang A
Cancer; 1987 May; 59(9):1577-81. PubMed ID: 3470110
[TBL] [Abstract][Full Text] [Related]
20. Ototoxicity of cis-diamminedichloroplatinum.
Vodvárka P; Foukalová J; Mrázek J; Philippová J
Neoplasma; 1985; 32(2):229-38. PubMed ID: 4039797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
